Deal Intelligence insights.
Trackers and analysis of major licensing and M&A transactions
Life Sciences M&A 2026: Trends & Strategic Analysis
$280B+ projected deal value. Patent cliff urgency, AI-driven targets, and Asia's emergence as a deal epicenter are reshaping the M&A landscape for life sciences executives.
Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis
$250B+ across 516 licensing deals in 2025. Average deal size surges 76% in 2026. Track the biggest transactions and what they mean for your BD strategy.
China Biotech Outbound Licensing Tracker 2026: $135.7B in Deal Value
Track every major China-to-global licensing deal. $135.7B cumulative value, AstraZeneca-CSPC $18.5B mega-deal, and BIOSECURE Act implications.
Pharma M&A Tracker 2026: Every Major Acquisition & What's Driving the Surge
$228B+ in pharma M&A in 2025. J&J-Intra-Cellular ($14.6B), Novartis-Avidity ($12B), and the patent cliff imperative reshaping deal strategy.
Pharma Deal Tracker 2026: The Definitive M&A & Licensing Roundup
$240 billion in life sciences M&A. $250 billion across 516 licensing deals. The biggest dealmaking year in pharma history—and what it means for 2026.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.